TrialPloS one2022
Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
Takashi Shigematsu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
TrialPloS one2022
Takashi Shigematsu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.